Q
Qi Xia
Researcher at Zhejiang University
Publications - 8
Citations - 731
Qi Xia is an academic researcher from Zhejiang University. The author has contributed to research in topics: Promoter & Cancer. The author has an hindex of 4, co-authored 7 publications receiving 669 citations.
Papers
More filters
Journal ArticleDOI
Clinical findings in 111 cases of influenza A (H7N9) virus infection
Hainv Gao,Hongzhou Lu,Bin Cao,Bin Du,Hong Shang,Jianhe Gan,Shuihua Lu,Yida Yang,Qiang Fang,Yinzhong Shen,Xiuming Xi,Qin Gu,Xian-Mei Zhou,Hong-Ping Qu,Zheng Yan,Fang-Ming Li,Wei Zhao,Zhancheng Gao,Guang-Fa Wang,Lingxiang Ruan,Weihong Wang,Jun Ye,Hui-Fang Cao,Xingwang Li,Wenhong Zhang,Xu-Chen Fang,Jian He,Weifeng Liang,Juan Xie,Mei Zeng,Xianzheng Wu,Jun Li,Qi Xia,Zhao-Chen Jin,Qi Chen,Chao Tang,Zhiyong Zhang,Bao-Min Hou,Zhi-Xian Feng,Jifang Sheng,Nanshan Zhong,Lanjuan Li +41 more
TL;DR: The presence of a coexisting medical condition was the only independent risk factor for the acute respiratory distress syndrome (ARDS) during the evaluation period, and the novel H7N9 virus caused severe illness, including pneumonia and ARDS, with high rates of ICU admission and death.
Journal ArticleDOI
A modified MELD model for Chinese pre-ACLF and ACLF patients and it reveals poor prognosis in pre-ACLF patients.
Qi Xia,Xiahong Dai,Yimin Zhang,Yongzheng Guo,Xiaowei Xu,Qian Yang,Weibo Du,Xiaoli Liu,Yuemei Chen,Jianrong Huang,Lanjuan Li +10 more
TL;DR: The findings of the present study suggest that the Chinese diagnostic criteria of ACLF might be broadened, thus enabling implementation of a novel model to predict ACLF-related death after comprehensive medical treatment.
Journal ArticleDOI
Downgrading MELD Improves the Outcomes after Liver Transplantation in Patients with Acute-on-Chronic Hepatitis B Liver Failure
Qi Ling,Xiao Xu,Qiang Wei,Xiaoli Liu,Haijun Guo,Li Zhuang,Jiajia Chen,Qi Xia,Haiyang Xie,Jian Wu,Shusen Zheng,Lanjuan Li +11 more
TL;DR: Downgrading MELD for liver transplant candidates with MELD score ≥30 was effective in improving patient prognosis, and an appropriate ALSS treatment within 48 h prior to LT is potentially beneficial.
Journal ArticleDOI
Relationship between TNF- gene promoter polymorphisms and outcomes of hepatitis B virus infections: a meta-analysis.
TL;DR: The data showed that polymorphisms -863 A and -308 G in the TNF- gene promoter region might be risk factors for HBV persistence and ethnicity might play an important role in HBV infection outcome, leading to conflicting results.
Journal ArticleDOI
Clinical efficacy of Methylprednisolone and the combined use of Lopinavir/Ritonavir with Arbidol in treatment of Coronavirus Disease 2019.
Qi Xia,Kaijin Xu,Qin Ni,Yongtao Li,Jun Liu,Hong Zhao,Yongzheng Guo,Liang Yu,Ping Yi,Junwei Su,Guanjing Lang,Jingjing Tao,Ding Shi,Wenrui Wu,Xiaoxin Wu,Yan Xu,Min Xu,Ling Yu,Xiaoyan Wang,Hongliu Cai,Qiang Fang,Jianying Zhou,Yunqing Qiu,Lanjuan Li +23 more
TL;DR: In this article, the therapeutic efficacy of multiple medication plans over Lopinavir/Ritonavir (LPV/r), Arbidol (ARB) and Methylprednisolone on patients with Coronavirus Disease 2019 (COVID-19) was analyzed.